Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer

Molecular Cancer Research

Volumn 9, Issue 12, 2011, Pages 1767-1779

  Tomek, Katharina ^a   Wagner, Renate ^a   Varga, Franz ^b   Singer, Christian F ^a   Karlic, Heidrun ^a   Grunt, Thomas W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b AUVA Soziale Unfallversicherung   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; C 75; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S6 KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHAGOSOME; CARCINOMA CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; LYSOSOME; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; UBIQUITINATION;

4-BUTYROLACTONE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CELL PROLIFERATION; CHROMONES; FATTY ACID SYNTHETASE COMPLEX; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOGENESIS; MORPHOLINES; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RIBOSOMAL PROTEIN S6 KINASES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; UBIQUITINATION;

EID: 84055207483     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0467     Document Type: Article

References (37)

1. Gao N, Flynn DC, Zhang Z, Zhong X, Walker V, Liu KJ, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 2004;287:C281-91. (Pubitemid 38955218)
2. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene Rev 2006;25:6436-46. (Pubitemid 44582287)
3. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Mol Cell 2002;10:151-62. (Pubitemid 34876569)
4. Graff JR, Konicek BW, Carter JH, Marcusson EG. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 2008;68:631-4. (Pubitemid 351206735)
5. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signalling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67. (Pubitemid 30428195)
6. de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, et al. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer 2008;99:341-9.
7. Lassus H, Leminen A, Vayrynen A, Cheng G, Gustafsson J, Isola J, et al. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 2004;92:31-9. (Pubitemid 38147368)
8. Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN, Butzow R. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med 2006;84:671-81. (Pubitemid 44164262)
9. Nielsen JS, Jakobsen E, Hølund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004; 14:1086-96. (Pubitemid 39603351)
10. Reibenwein J, Krainer M. Targeting signaling pathways in ovarian cancer. Expert Opin Ther Targets 2008;12:353-65. (Pubitemid 351419428)
11. Alò PL, Visca P, Framarino ML, Botti C, Monaco S, Sebastiani V, et al. Immunohistochemical study of fatty acid synthase in ovarian neoplasms. Oncol Rep 2000;7:1383-8.
12. Gansler TS, Hardman W, Hunt DA, Schaffel S, Hennigar RA. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 1997;28:686-92. (Pubitemid 27258421)
13. Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A, et al. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 2005;24:3574-82. (Pubitemid 40756227)
14. Pizer ES, Wood FD, Heine HS, Romantsev FE, Pasternack GR, Kuhajda FP. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 1996;56: 1189-93. (Pubitemid 26080952)
15. Grunt TW, Wagner R, Grusch M, Berger W, Singer CF, Marian B, et al. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Comm 2009;385:454-9.
16. Grunt TW, Tomek K, Wagner R, Puckmair K, Kainz B, Rünzler D, et al. Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways. J Cell Physiol 2007;211:803-15. (Pubitemid 46683048)
17. Brünner-Kubath C, Shabbir W, Saferding V, Wagner R, Singer CF, Valent P, et al. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat 2011;129:387-400.
18. Thupari JN, Landree LE, Ronnett GV, Kuhajda FP. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A 2002;99:9498-502. (Pubitemid 34764642)
19. Bentebibel A, Sebastián D, Herrero L, López-Viñas E, Serra D, Asins G, et al. Novel effect of C75 on carnitine palmitoyltransferase I activity and palmitate oxidation. Biochemistry 2006;45:4339-50.
20. Puig T, Turrado C, Benhamú B, Aguilar H, Relat J, Ortega-Gutiérrez S, et al. Novel inhibitors of fatty acid synthase with anticancer activity. Clin Cancer Res 2009;15:7608-15.
21. Bandyopadhyay S, Zhan R, Wang Y, Pai SK, Hirota S, Hosobe S, et al. Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells. Cancer Res 2006;66: 5934-40. (Pubitemid 43927149)
22. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004;22:304-11. (Pubitemid 38725184)
23. Raben N, Shea L, Hill V, Plotz P. Monitoring autophagy in lysosomal storage disorders. Methods Enzymol 2009;453:417-49.
24. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81. (Pubitemid 39446895)
25. WuG, Xing M,Mambo E, Huang X, Liu J,Guo Z, et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 2005;7:R609-16.
26. Little JL, Wheeler FB, Fels DR, Koumenis C, Kridel SJ. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res 2007;67:1262-9.
27. Dai R, Chen R, Li H. Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death inhuman hepatocellular carcinoma cells. Int J Oncol 2009;34:1749-57.
28. Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, Lane MD, et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000;288:2379-81. (Pubitemid 30448165)
29. Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 2010;6: 551-62.
30. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4:988-1004.
31. Karbowniczek M, Robertson GP, Henske EP. Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization. J Biol Chem 2006;281: 25447-56. (Pubitemid 44401933)
32. Lu Z, Liu D, Hornia A, Devonish W, Pagano M, Foster DA. Activation of protein kinase C triggers its ubiquitination and degradation. Mol Cell Biol 1998;18:839-45. (Pubitemid 28063417)
33. Brickley DR, Mikosz CA, Hagan CR, Conzen SD. Ubiquitin modification of serum and glucocorticoid-induced protein kinase-1 (SGK-1). J Biol Chem 2002;277:43064-70. (Pubitemid 35285688)
34. Bogusz AM, Brickley DR, Pew T, Conzen SD. A novel N-terminal hydrophobic motif mediates constitutive degradation of serum- and glucocorticoid-induced kinase-1 by the ubiquitin-proteasome pathway. FEBS J 2006;273:2913-28.
35. Wang M, Panasyuk G, Gwalter J, Nemazanyy I, Fenton T, Filonenko V, et al. Regulation of ribosomal protein S6 kinases by ubiquitination. Biochem Biophys Res Comm 2008;369:382-7.
36. Gwalter J, Wang ML, Gout I. The ubiquitination of ribosomal S6 kinases is independent from the mitogen-induced phosphorylation/activation of the kinase. Int J Biochem Cell Biol 2009;41: 828-33.
37. Knowles LM, Smith JW. Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer. BMC Genomics 2007;8:168-81.